Article

Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical Trials

2024-05-16

Abstract excerpt

<h4>Background: </h4> Metabolic dysfunction-associated steatotic liver disease (MASLD) significantly impacts global health, with a prevalence affecting roughly 25% of adults worldwide. GLP-1 receptor agonists (GLP-1RAs) offer potential therapeutic benefits beyond glycemic control, including improvement in hepatic steatosis, inflammation, and fibrosis. <h4>Objectives: </h4> This study aims to systematically review...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ebe5312b-ce19-5d09-a9ff-5806e249bd65
DOI: 10.22541/au.171585503.34303032/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of GLP-1 Receptor Agonists in Patients with MASLD: A Systematic Review and Meta-analysis of Randomized Clinical TrialsDOI 10.22541/au.171585503.34303032/v1Read

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and ChallengesSemantic proximity Read

Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging TherapiesSemantic proximity Read

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtypingSemantic proximity Read

<i>Lodhrasavam</i> modulates liver–adipose–pancreas axis to ameliorate MASLD: Observations from <i>In vitro</i> and <i>in vivo</i> models of hepatic and metabolic dysfunctionSemantic proximity Read

Hepatokines and MASLD: The GLP1-Ras-FGF21-Fetuin-A Crosstalk as a Therapeutic TargetSemantic proximity Read

NAFLD/MASLD and the Gut–Liver Axis: From Pathogenesis to Treatment OptionsSemantic proximity Read

The Effect of Cardiometabolic Drugs on Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Semantic proximity Read

Exploring the Role of Probiotics, Prebiotics, and Synbiotics in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease—A Scoping ReviewSemantic proximity Read

<i>Patolakaturohiniyadi Kashayam</i> , exerts anti-steatotic and anti-obesogenic effects via coordinated regulation of lipid metabolism, inflammation, and incretin signallingSemantic proximity Read

Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae.Semantic proximity Read

The Efficacy of Food Bioactive Compounds in The Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisSemantic proximity Read

Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p as potential predictive biomarkers for Metabolic Dysfunction-Associated Steatotic Liver Disease assessmentSemantic proximity Read